nderstanding and monitoring renal microvascular remodeling in CKD by super-resolution ultrasound

niklinik RWTH Aachen0 个研究点目标入组 50 人开始时间: 2024年8月13日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Patients after kidney transplantation with GFR = 20 ml/min (Study part A)
•2. Patients with CKD with GFR = 20 ml/min (Study part B)
•3. Written consent
•4. Patients who are contractually capable and able to follow the requests of the study staff

•2. allergy against ultrasound contrast agent or components sulfur hexafluoride, macrogol 4000, Colfoscerilstearat, 1-(1,2-Dipalmitoyl-3-sn-phosphatidyl)glycerol-Natriumsalt Palmitic acid
•3. Left-right -shunt
•4. signs of cardiovascular instability such as acute coronary syndrome, clinically instable ischemic heart disease, acute myocardial infarction, angina pectoris within 7 days prior, recent coronary intervention (PTA with or without stent), acute cardiac failure, cardiac insufficiency NYHA III or IV, severe arrhythmias
•5. acute endocarditis
•6. artificial heart valves
•7. acute systemic inflammation and/or sepsis
•8. coagulopathy or recent thromboembolic event
•9. liver or kidney disease in end stage
•10. severe pulmonary hypertension (pA pressure >90mmHg)
•11. uncontrolled systemic hypertension
•12. acute respiratory distress syndrome
•13. clinically significant pulmonary disease including severe COPD
•14. pregnancy
•15. persons under official directive (prisoners, e.g.)
•16. persons who are working for the sponsor or are dependent of the sponsor
•17. alcohol or drug misuse
•18. expected non-compliance

发起方

niklinik RWTH Aachen